BGI Genomics Co., Ltd. (SHE:300676)
China · Delayed Price · Currency is CNY 40.28
-0.94 (-2.28%)
Apr 28, 2026, 3:04 PM CST
BGI Genomics Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 3,824 | 3,687 | 3,842 | 4,333 | 7,036 | 6,754 |
Other Revenue | 18.56 | 18.56 | 24.6 | 16.91 | 16.67 | 11.75 |
| 3,842 | 3,705 | 3,867 | 4,350 | 7,053 | 6,766 | |
Revenue Growth (YoY) | 3.35% | -4.18% | -11.10% | -38.33% | 4.24% | -19.42% |
Cost of Revenue | 2,544 | 2,436 | 2,364 | 2,202 | 3,528 | 2,845 |
Gross Profit | 1,298 | 1,270 | 1,503 | 2,147 | 3,526 | 3,921 |
Selling, General & Admin | 1,094 | 1,108 | 1,424 | 1,441 | 1,998 | 1,637 |
Research & Development | 424.58 | 453.17 | 601.38 | 523.23 | 526.46 | 474.79 |
Other Operating Expenses | 20.62 | 17.71 | 16.77 | 4.1 | -89 | 24.06 |
Operating Expenses | 1,817 | 1,864 | 2,240 | 2,035 | 2,620 | 2,241 |
Operating Income | -518.3 | -594.6 | -736.53 | 112.94 | 905.27 | 1,680 |
Interest Expense | -37.85 | -36.04 | -52.02 | -91.56 | -100.76 | -104.72 |
Interest & Investment Income | 87.93 | 100.36 | 125.72 | 153.33 | 424.36 | 218.16 |
Currency Exchange Gain (Loss) | 15.13 | 15.13 | -19.09 | -11.36 | -2.27 | -39.76 |
Other Non Operating Income (Expenses) | -6.27 | -7.9 | -3.41 | -35.86 | -91.43 | -4.04 |
EBT Excluding Unusual Items | -459.36 | -523.06 | -685.33 | 127.49 | 1,135 | 1,750 |
Impairment of Goodwill | - | - | -10.64 | - | - | - |
Gain (Loss) on Sale of Investments | -14.98 | -11.29 | -87.41 | -34.36 | 80.73 | 86.41 |
Gain (Loss) on Sale of Assets | 2.15 | 0.6 | -0.1 | 2.76 | 0.11 | -3.88 |
Asset Writedown | -82.96 | -79.94 | -125.97 | -9.25 | -209.24 | -102.24 |
Other Unusual Items | 11.35 | 11.35 | 23.33 | 28.89 | 0.02 | 15.87 |
Pretax Income | -543.8 | -602.34 | -886.11 | 115.54 | 1,007 | 1,746 |
Income Tax Expense | 48.64 | 35.47 | 25.99 | 21.85 | 197.51 | 268.19 |
Earnings From Continuing Operations | -592.44 | -637.81 | -912.1 | 93.68 | 809.29 | 1,478 |
Minority Interest in Earnings | 18.96 | 21.15 | 9.41 | -0.78 | -6.52 | -16.16 |
Net Income | -573.48 | -616.66 | -902.69 | 92.9 | 802.77 | 1,462 |
Net Income to Common | -573.48 | -616.66 | -902.69 | 92.9 | 802.77 | 1,462 |
Net Income Growth | - | - | - | -88.43% | -45.07% | -30.08% |
Shares Outstanding (Basic) | 417 | 416 | 412 | 410 | 410 | 410 |
Shares Outstanding (Diluted) | 417 | 416 | 412 | 412 | 410 | 412 |
Shares Change (YoY) | 0.98% | 0.96% | 0.01% | 0.48% | -0.32% | 3.11% |
EPS (Basic) | -1.37 | -1.48 | -2.19 | 0.23 | 1.96 | 3.56 |
EPS (Diluted) | -1.37 | -1.48 | -2.19 | 0.23 | 1.96 | 3.55 |
EPS Growth | - | - | - | -88.48% | -44.90% | -32.25% |
Free Cash Flow | -356.11 | -569.14 | -433.76 | -827.62 | -1,136 | 2,093 |
Free Cash Flow Per Share | -0.85 | -1.37 | -1.05 | -2.01 | -2.77 | 5.08 |
Dividend Per Share | - | - | - | 0.100 | 1.000 | 0.350 |
Dividend Growth | - | - | - | -90.00% | 185.71% | - |
Gross Margin | 33.79% | 34.27% | 38.87% | 49.37% | 49.99% | 57.95% |
Operating Margin | -13.49% | -16.05% | -19.05% | 2.60% | 12.83% | 24.83% |
Profit Margin | -14.93% | -16.64% | -23.34% | 2.14% | 11.38% | 21.60% |
Free Cash Flow Margin | -9.27% | -15.36% | -11.22% | -19.03% | -16.10% | 30.93% |
EBITDA | -53.29 | -136.61 | -306.66 | 482.76 | 1,262 | 1,959 |
EBITDA Margin | -1.39% | -3.69% | -7.93% | 11.10% | 17.90% | 28.95% |
D&A For EBITDA | 465.01 | 457.98 | 429.87 | 369.81 | 357.13 | 278.78 |
EBIT | -518.3 | -594.6 | -736.53 | 112.94 | 905.27 | 1,680 |
EBIT Margin | -13.49% | -16.05% | -19.05% | 2.60% | 12.83% | 24.83% |
Effective Tax Rate | - | - | - | 18.92% | 19.62% | 15.36% |
Revenue as Reported | 3,842 | 3,705 | 3,867 | 4,350 | 7,053 | 6,766 |
Updated Mar 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.